BioTuesdays

Author - Kany Doski

Corium International
Markets

HCW starts Corium at buy

H.C. Wainwright initiated coverage of Corium International (NASDAQ:CORI) with a “buy” rating and $15 price target. The stock closed at $10.88 on Sept. 25. Corium is a pure-play transdermal (TD) patch dug delivery...

September 26, 2017
Genocea Biosciences
Markets

Stifel cuts Genocea to hold, price target to $2.50

Stifel downgraded Genocea Biosciences (NASDAQ:GNCA) to “hold” from “buy” and slashed its price target to $2.50 from $15 after the company shifted its strategic focus. The stock closed at $5.33 on Sept. 25. “We believe...

September 26, 2017
ProMIS Neurosciences
Markets

Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD)...

September 19, 2017
Applied Genetic
Markets

HCW cuts Applied Genetic price target to $8

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended...

September 13, 2017
Innate Pharma Logo
Markets

HCW starts Innate Pharma at buy

H.C. Wainwright initiated coverage of French-based Innate Pharma (PSE:IPH) with a “buy” rating and price target of €16.50. The stock closed at €10.70 on August 29. Analyst Swayampakula Ramakanth writes that Innate is...

August 30, 2017
CymaBay
Markets

Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22. CymaBay is currently developing seladelpar for the lead...

August 23, 2017
IRadimed
Markets

Roth ups iRadimed to buy

Roth Capital Partners upgraded iRadimed (NASDAQ:IRMD) to “buy” from “neutral” and raised its price target to $12 from $9 after the company reported second quarter results. The stock closed at $9.80 on July 31. iRadimed...

August 1, 2017
AxoGen
Markets

Leerink starts Axogen at OP

Leerink launched coverage of Axogen (NASDAQ:AXGN) with an “outperform” rating and $22 price target. The stock closed at $15.10 on July 28. “We see Axogen as a unique and sustainable high-growth company, with a unique...

July 31, 2017
AzurRx BioPharma
Markets

HCW starts AzurRx at buy

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24. AzurRx is developing a novel recombinantly produced pancreatic lipase...

July 25, 2017